Real-world multicenter outcomes of CD3xCD20 bispecific antibody therapies in patients with central nervous system (CNS) lymphoma

医学 淋巴瘤 内科学 肿瘤科 双特异性抗体 弥漫性大B细胞淋巴瘤 原发性中枢神经系统淋巴瘤 套细胞淋巴瘤 中枢神经系统 全身性疾病 化疗 疾病 美罗华 B细胞淋巴瘤 抗体 无进展生存期 放射治疗 免疫学 病理 回顾性队列研究 大细胞淋巴瘤 存活率
作者
Karan Chohan,James L. Godfrey,Steven M. Bair,Lorenzo Falchi,Manali Kamdar,Ajay Major,Sonia Godbole,Gilles Salles,Omnia Farahat,Amy Ayers,Amrita Chauhan,Alex F. Herrera,Geoffrey Shouse,Sairah Ahmed,Yazeed Sawalha
出处
期刊:Blood [Elsevier BV]
卷期号:146 (Supplement 1): 5520-5520
标识
DOI:10.1182/blood-2025-5520
摘要

Abstract Introduction: CNS involvement in B-cell non-Hodgkin lymphoma (B-NHL) results in poor outcomes and remains an unmet need. The CD3xCD20 bispecific antibodies (BsAb) are effective in systemic B-NHL, but data on the CNS activity of BsAbs are limited. Herein, we report real-world outcomes of CD3xCD20 BsAb in patients (pts) with CNS involvement by B-NHL. Methods: This is a multicenter retrospective study of adult pts with B-NHL with active or history of CNS involvement treated with commercial CD3xCD20 BsAb at 5 US medical centers as part of the Collaborative US Bispecific Consortium (CUBIC). Responses were determined using PET/CT for systemic involvement and brain MRI and/or CSF analysis for CNS involvement. Progression-free survival (PFS) was calculated from BsAb initiation to disease progression (PD) or death, and overall survival (OS) from BsAb initiation to death. Results: We included 20 pts who received BsAb (glofitamab n=15, epcoritamab n=3, mosunetuzumab n=2) from 9/2023 to 11/2024. Twelve pts received BsAb alone and 8 combined with systemic therapy (acalabrutinib/zanubrutinib n=4, polatuzumab n=3) and/or radiation (RT, n=4). Median age was 68 years, 55% were male, and 45% had ECOG ≥2. Twelve pts had diffuse large B cell lymphoma (DLBCL), 3 primary CNS lymphoma (PCNSL), 2 high-grade B cell lymphoma (HGBL), 2 mantle cell lymphoma (MCL), and 1 Burkitt (BL). At BsAb initiation, 60% (n=12) of pts had CNS disease: 92% (n=11) with parenchymal disease and 33% (n=4) with leptomeningeal disease (3 had both). Three pts (25%) had isolated CNS disease and 75% (n=9) had concurrent systemic disease. Eight pts (40%) had a history of CNS disease without active involvement at time of BsAb initiation. Pts received a median of 2 (range, 2-8) prior lines of therapy, including chimeric antigen receptor (CAR) T cell therapy in 65% (n=13; median 7 months from CAR T to BsAb), CNS RT in 60% (n=12; median 4 months from RT to BsAb), and intrathecal chemotherapy in 70% (n=14). The best overall response rate (ORR) (CNS + systemic, 1 unevaluable) was 58% (11/19) including complete response (CR) in 37% (7/19) and partial response (PR) in 21% (4/19). The ORR and CR rate were 58%/33% in DLBCL, 67%/67% PCNSL, 50%/50% HGBL, 100%/0% MCL (1 pt evaluable), and 0% BL. ORR and CR rates were similar irrespective of prior CAR T (p=.31, p=.68), choice of BsAb (p=.92, p=.50), or receipt of BsAb alone vs in combination (p=.09, p=.36). In pts with CNS disease at BsAb initiation (n=12), the best ORR (systemic + CNS) was 50% (6/12) including CR in 25% (3/12) and PR in 25% (3/12). The ORR and CR rate were 50% (3/6) and 33% (2/6) with BsAb monotherapy, and 50% (3/6) and 17% (1/6) with BsAb combination. Evaluating CNS-specific responses (n=11, 1 unevaluable), the best CNS ORR was 55% (6/11) including CR in 27% (3/11) and PR in 27% (3/11). Median time to first CNS response was 53 days (range, 19-113), with 83% of responding pts achieving response within 60 days. In pts without active CNS disease, (n=7; 1 unevaluable), the best ORR was 71% (5/7) including CR in 57% (4/7) and PR in 14% (1/7). The ORR and CR rate were 80% (4/5) and 60% (3/5) with BsAb monotherapy, and 50% (1/2) and 50% (1/2) with BsAb combination. With median follow-up of 7 months (95% confidence interval (CI), 5-not reached), among the whole cohort, the 6-month PFS and OS were 39% (95% CI, 21-71) and 75% (95%CI, 58-97), respectively. The 6-month PFS and OS were similar with BsAb monotherapy (38% [95% CI, 18-81] and 75% [95% CI, 54-100]) compared with BsAb combination (42% [16-100%] [p=.99] and 75% [50-100%] [p=.91]), respectively. PFS and OS were similar irrespective of lymphoma subtype (PFS, p=.61; OS, p=.78), prior CAR T (PFS, p=.34; OS, p=.72), or BsAb agent (PFS, p=.89; OS, p=.62). Among pts with CNS disease at BsAb initiation, the 6-month CNS PFS was 65% (95% CI, 38-100%). No patients achieving CNS CR had CNS relapse at last follow-up. Among pts without active CNS disease at BsAb initiation, only 1 pt had CNS relapse. Any grade (G) CRS occurred in 35% (n=7, all G1-2). Any G ICANS occurred in 15% (n=3; 2 G1, and 1 suspected G4). Conclusion: Our study shows significant clinical activity for the CD3xCD20 BsAb, alone and in combination, in B-NHL with CNS involvement (CNS-specific ORR and CR rate of 55% and 27%, respectively) without new safety concerns. Larger studies, ideally prospective, are needed to confirm the efficacy and safety of CD3xCD20 BsAb in pts with CNS involvement by B-NHL.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
幸运的锦发布了新的文献求助10
1秒前
1秒前
成就书包发布了新的文献求助10
1秒前
王八发布了新的文献求助10
1秒前
安诺发布了新的文献求助30
1秒前
所所的应助被花痴的文昊采纳,获得10
2秒前
壮壮发布了新的文献求助20
2秒前
宅宅发布了新的文献求助10
2秒前
2秒前
2秒前
核桃的应助被苏靖采纳,获得20
3秒前
合梦易发布了新的文献求助10
3秒前
大气的烧鹅完成签到,获得积分10
3秒前
3秒前
温暖访枫发布了新的文献求助10
3秒前
pppl发布了新的文献求助10
3秒前
dcm发布了新的文献求助10
3秒前
3秒前
3秒前
打打的应助被SanXing三醒采纳,获得10
4秒前
西洲完成签到,获得积分10
4秒前
4秒前
potato发布了新的文献求助10
4秒前
JamesPei的应助被MW采纳,获得10
4秒前
渔夫完成签到,获得积分10
4秒前
5秒前
5秒前
领导范儿的应助被leo采纳,获得10
5秒前
5秒前
4444455555555完成签到,获得积分10
5秒前
5秒前
领导范儿的应助被喜悦桥采纳,获得20
5秒前
伶俐衣完成签到,获得积分10
6秒前
6秒前
qqe发布了新的文献求助10
6秒前
6秒前
6秒前
雾很玫瑰的应助被墨尘采纳,获得10
8秒前
8秒前
Gt完成签到,获得积分10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8162621
求助须知:如何正确求助?哪些是违规求助? 9556889
关于积分的说明 21737583
捐赠科研通 7753002
什么是DOI,文献DOI怎么找? 3427836
关于科研通互助平台的介绍 2552719
邀请新用户注册赠送积分活动 2472507